HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Online-Only Appendix All Versions of this Article: dc06-2272v1 30/7/1689    most recent Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kahler, K. H. Articles by Pogach, L. M. Search for Related Content PubMed PubMed Citation Articles by Kahler, K. H. Articles by Pogach, L. M. Social Bookmarking                What's this?

Impact of oral anti-hyperglycemic therapy on all-cause mortality among patients with diabetes in the Veterans Health Administration

¹Center for Health Care Knowledge and Management, VA New Jersey Health Care System
²Center for Health Care Knowledge and Management, VA New Jersey Health Care System
³University of Medicine and Dentistry of New Jersey, School of Public Health
⁴Deep South Center on Effectiveness, Birmingham VA Medical Center
⁵University of Medicine and Dentistry of New Jersey, School of Public Health
⁶University of Medicine and Dentistry of New Jersey, School of Public Health
⁷Center for Health Care Knowledge and Management, VA New Jersey Health Care System

kristijan.kahler{at}novartis.com

ABSTRACT

Objective:The objective of this analysis was to evaluate the impact of several classes of oral anti-hyperglycemic therapy relative to sulfonylurea monotherapy on all-cause mortality among a cohort of patients with diabetes from the Veterans Health Administration (VHA).

Research Design and Methods:A retrospective cohort study using data obtained from the VHA Diabetes Epidemiology Cohort was employed. Users of oral anti-hyperglycemic therapy were classified into the following cohorts: sulfonylurea monotherapy, metformin monotherapy, metformin + sulfonylurea, TZD use alone or in combination with other oral agents (TZD users), and no drug therapy. All-cause mortality was the outcome of interest. Multivariate mixed models incorporating a propensity score to account for imbalance among cohorts were used to estimate drug effects on mortality with associated 95% confidence intervals (95%CI).

Results:39,721 patients with diabetes were included in the study. Adjusted odds ratios and 95%CIs for all-cause mortality were 0.87 (0.68, 1.10) for metformin monotherapy users, 0.92 (0.82, 1.05) for metformin + sulfonylurea users, 1.04 (0.75, 1.46) for TZD users, relative to sulfonylurea monotherapy users.

Conclusions:We did not find any significant drug effect on all-cause mortality for any oral treatment cohorts relative to sulfonylurea oral-monotherapy.

CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				Z. T. Bloomgarden Approaches to Treatment of Type 2 Diabetes Diabetes Care, August 1, 2008; 31(8): 1697 - 1703. [Full Text] [PDF]

				A. D. Rao, N. Kuhadiya, K. Reynolds, and V. A. Fonseca Is the Combination of Sulfonylureas and Metformin Associated With an Increased Risk of Cardiovascular Disease or All-Cause Mortality?: A meta-analysis of observational studies Diabetes Care, August 1, 2008; 31(8): 1672 - 1678. [Abstract] [Full Text] [PDF]

				J. H. Halanych, M. M. Safford, W. C. Keys, S. D. Person, J. M. Shikany, Y.-I. Kim, R. M. Centor, and J. J. Allison Burden of Comorbid Medical Conditions and Quality of Diabetes Care Diabetes Care, December 1, 2007; 30(12): 2999 - 3004. [Abstract] [Full Text] [PDF]